U.S. markets open in 2 hours 33 minutes

Fennec Pharmaceuticals Inc. (FENC)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
9.31+0.26 (+2.87%)
At close: 04:00PM EST
9.31 0.00 (0.00%)
After hours: 05:38PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Relative Strength Index (RSI)

Relative Strength Index (RSI)

Previous Close9.05
Bid0.00 x 900
Ask0.00 x 800
Day's Range9.07 - 9.35
52 Week Range6.30 - 10.85
Avg. Volume100,306
Market Cap248.665M
Beta (5Y Monthly)0.34
PE Ratio (TTM)N/A
EPS (TTM)-0.75
Earnings DateNov 06, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est16.17
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for FENC

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Fennec Pharmaceuticals Inc.
    Analyst Report: Johnson & JohnsonJohnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women’s health. The consumer group is being divested in 2023 under the new name Kenvue. Geographically, just over half of total revenue is generated in the United States.
    Fair Value
    Economic Moat
    2 days agoMorningstar
View more
  • Simply Wall St.

    With 31% stake, Fennec Pharmaceuticals Inc. (NASDAQ:FENC) seems to have captured hedge funds investors' interest

    Key Insights Institutions' substantial holdings in Fennec Pharmaceuticals implies that they have significant influence...

  • GlobeNewswire

    Fennec Announces Incremental $5 Million Investment from Petrichor

    ~ Supports Strategic Discussions and Global Launch Activities ~ ~ Extends Access to Additional Undrawn Capital As Needed During Global PEDMARK® Rollout ~ ~ Facilitates Market Expansion into the Adolescent and Young Adult (AYA) Patient Population ~ RESEARCH TRIANGLE PARK, N.C., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company focused on improving the lives of children with cancer, today announced the third

  • GlobeNewswire

    Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences

    RESEARCH TRIANGLE PARK, N.C., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will be participating in upcoming conferences. The management team will also host one-on-one investor meetings at the conferences. Presentation Details: Event: Jefferies London Healthcare Conference in London, UKDate: November 16, 2023Time: Company Presentation at 5:00 a.m. ET / 10:00 a.m. GMT Ev